Mary Ellen Schneider

All articles by Mary Ellen Schneider

Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients

By

Mary Ellen Schneider

May 5, 2023

The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.

Next post in Lymphoma

A patient is being prepared for HSCT.

Lenalidomide Maintenance Not Recommended After ASCT in High-Risk Non-Hodgkin Lymphoma